Hillstream Biopharma (CNTN) versus Its Peers Financial Survey

Hillstream Biopharma (NASDAQ:CNTN) is one of 226 public companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Hillstream Biopharma to related businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Profitability

This table compares Hillstream Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-35.59%	-27.05%
Hillstream Biopharma Competitors	-4,799.00%	-250.01%	-47.92%

Valuation and Earnings

This table compares Hillstream Biopharma and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Hillstream Biopharma	N/A	-$35.92 million	-0.75
Hillstream Biopharma Competitors	$330.10 million	-$26.88 million	-4.58

Hillstream Biopharma’s rivals have higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Hillstream Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1	0	0	0	1.00
Hillstream Biopharma Competitors	2232	2463	4375	69	2.25

As a group, “Pharmaceutical Preparations” companies have a potential upside of 113.47%. Given Hillstream Biopharma’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Hillstream Biopharma has less favorable growth aspects than its rivals.

Volatility and Risk

Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Hillstream Biopharma’s rivals have a beta of 12.09, suggesting that their average share price is 1,109% more volatile than the S&P 500.

Insider and Institutional Ownership

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Hillstream Biopharma rivals beat Hillstream Biopharma on 9 of the 13 factors compared.

Hillstream Biopharma Company Profile

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.